CLINICAL_TRIALS trial_result · 2016-10-04

Clinical Trial Update: Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor [Phase 2]

Phase 2 trial of the Hsp90 inhibitor AUY922 for refractory gastrointestinal stromal tumors has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: SCRI Development Innovations, LLC | Conditions: Gastrointestinal Stromal Tumor | Phase 2 | Status: COMPLETED | Results posted: 2016-10-04